2 results
Approved WMORecruiting
Primary, improvement of the quality of life.Secondary, reduction of pain and a decrease of the number of treatments by a breast oedema therapist.
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.